Journal: Clinical and Experimental Immunology

Article Title: Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4 + T cells partly via transforming growth factor‐ β 1

doi: 10.1111/cei.12870

Figure Lengend Snippet: Transforming growth factor (TGF)‐β1 diminishes the ability of tolerogenic dendritic cells (tolDC) to stimulate healthy control (HC) T cells and is involved in their regulatory function. (a–d) Mature lipopolysaccharide (LPS)‐activated dendritic cells (matDC) or tolDC (1 × 104 cells/well) were co‐cultured with allogeneic HC CD4+ T cells (1 × 105 cells/well) in the absence or presence of increasing concentrations of SB‐505124, a small molecule inhibitor of TGF‐βRI (a) or 1 μM SB‐505124 (b,c) or increasing concentrations of recombinant latency‐associated peptide (LAP) (d). Proliferation (a,b,d, left panels), measured using [3H]‐thymidine uptake, and interferon (IFN)‐γ production (a,b,d, right panels), measured using enzyme‐linked immunosorbent assay (ELISA), were assessed at day 6. (c) Additional cytokines were detected in day 6 culture supernatants from tolDC‐CD4+ T‐cell cultures using an ELISA [interleukin (IL)−17A] or Meso Scale Discovery (MSD) immunoassay (all others). The fold change in cytokine production following inhibition of TGF‐β1 signalling was calculated by: concentration of cytokine produced in the presence of 1μM SB‐505124 ÷ concentration of cytokine produced in the absence of 1 μM SB‐505124. IL‐17A was undetectable in one experiment. Error bars in (a) and (d) represent standard error of the mean (s.e.m.) of triplicates (proliferation) or duplicates (IFN‐γ production). Horizontal lines in (b) and (c) represent median values, (b) left panel (proliferation) n = 7; (b) right panel (IFN‐γ production) n = 15; (c) (cytokines) n = 3. (e) Allogeneic healthy control (HC) CD4+ T cells were primed with DC (10 : 1) for 6 days and rested for 4 days with 10 IU/ml IL‐2. T cell lines primed by matDC (Tmat), tolDC (Ttol) and tolDC + SB‐505124 (Ttol‐SB) were restimulated with matDC and IFN‐γ (left panel) and IL‐10 (right panel) production, measured using ELISA, was assessed on day 3. Results are depicted as the percentage cytokine production of Tmat cell lines. Cytokine concentrations range: IFN‐γ in Ttol = 0.9–20·6 ng/ml and in Ttol‐SB = 4·4–80·7 ng/ml; IL‐10 in Ttol = 0·4–5·1 ng/ml and in Ttol‐SB = 0·9–31·7 ng/ml. Horizontal lines represent median values, n (IFN‐γ production) = 7; n (IL‐10 production) = 6. *P < 0·05 and ***P < 0·0001 calculated with Wilcoxon signed‐rank test. #Significant differences (P < 0·05) between Ttol and Tmat cells.

Article Snippet: TGF‐βRI (ALK5) inhibitor (SB‐505124; Sigma) or recombinant human LAP (R&D Systems) was added where indicated.

Techniques: Control, Cell Culture, Recombinant, Enzyme-linked Immunosorbent Assay, Inhibition, Concentration Assay, Produced

Journal: Anticancer research

Article Title: Intraductal Adaptation of the 4T1 Mouse Model of Breast Cancer Reveals Effects of the Epithelial Microenvironment on Tumor Progression and Metastasis

doi: 10.21873/anticanres.13344

Figure Lengend Snippet: Tumor sphere formation and drug sensitivity. A: Representative image of 4T1 tumor sphere (scale bar=100 μm). B: Numbers of primary and secondary 4T1 tumor spheres (n=3). C: Lapatinib reduced 4T1 tumor sphere formation. D: Inhibitor of activin-like kinase 4/5/7 receptor signaling SB-505124 had no effect on 4T1 tumor sphere formation. Data are presented as the mean±standard error. DMSO: Dimethyl sulfoxide; SFE: Sphere-forming efficiency.

Article Snippet: Lapatinib (Santa Cruz Dallas, TX, USA) and SB-505124 (Sigma) were diluted in dimethyl sulfoxide (DMSO).

Techniques:

Journal: STAR Protocols

Article Title: Protocol for efficient generation of human artery and vein endothelial cells from pluripotent stem cells

doi: 10.1016/j.xpro.2024.103494

Figure Lengend Snippet: Resuspension of lyophilized growth factors and small molecules needed for differentiation

Article Snippet: SB505124 , Tocris , 3263.

Techniques: Concentration Assay

Journal: STAR Protocols

Article Title: Protocol for efficient generation of human artery and vein endothelial cells from pluripotent stem cells

doi: 10.1016/j.xpro.2024.103494

Figure Lengend Snippet: 10 mL of lateral mesoderm differentiation medium (for day 2 of hPSC differentiation)

Article Snippet: SB505124 , Tocris , 3263.

Techniques: Concentration Assay, Generated

Journal: STAR Protocols

Article Title: Protocol for efficient generation of human artery and vein endothelial cells from pluripotent stem cells

doi: 10.1016/j.xpro.2024.103494

Figure Lengend Snippet: 10 mL of vein EC differentiation medium A (for day 3 of hPSC differentiation)

Article Snippet: SB505124 , Tocris , 3263.

Techniques: Concentration Assay, Generated

Journal: STAR Protocols

Article Title: Protocol for efficient generation of human artery and vein endothelial cells from pluripotent stem cells

doi: 10.1016/j.xpro.2024.103494

Figure Lengend Snippet: 10 mL of vein EC differentiation medium B (for day 4 of hPSC differentiation)

Article Snippet: SB505124 , Tocris , 3263.

Techniques: Concentration Assay, Generated

Journal: STAR Protocols

Article Title: Protocol for efficient generation of human artery and vein endothelial cells from pluripotent stem cells

doi: 10.1016/j.xpro.2024.103494

Figure Lengend Snippet:

Article Snippet: SB505124 , Tocris , 3263.

Techniques: Recombinant, Membrane, Pore Size